Sustained Therapeutics

11:00 AM - 11:15 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104B
Sustained Therapeutics is a clinical stage company developing non-opioid medicines for the treatment of pain. Our novel sustained-release delivery platform has the potential to provide effective, long-lasting solutions for both acute and chronic pain.

Not only are Sustained's products non-addictive, but their durability provides a significant competitive advantage – they offer up to four weeks of pain relief from a single injection, compared to only one to three days from competitive products.

A successful Phase I clinical trial demonstrated the feasibility of our approach. Two Phase II studies are underway, one in post-operative pain and one in chronic pain.

We believe that our patented drug delivery platform platform can also support the development of therapeutics for fibrotic, urological and inflammatory diseases, as well as some types of cancer. Planning for our first oncology trial is underway, and we anticipate initiating a Phase II oncology trial in late 2023.
Company Type:
Privately Funded Company
Company HQ State:
British Columbia
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
ST-01 for acute and chronic pain
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
Sustained Therapeutics